Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies.
R estless legs syndrome (RLS) is a frequent neurological disorder and one of the most common sleep disorders. Four essential criteria are obligatory for the clinical diagnosis. These criteria were established and revised by the International RLS Study Group. 1 Because of RLS symptoms and/or periodic leg movement, initiating and maintaining sleep often are complicated and disrupted. Whereas insomnia is a common complain in RLS, little is known about the existence of excessive daytime sleepiness (EDS). In a few studies, 2Y4 a subpopulation of RLS patients with daytime sleepiness (Epworth Sleepiness Scale [ESS] 5 score, 910) has been identified. Pathophysiology and predictors of EDS in RLS still remain unclear, and there is little information on the evolution of EDS under different RLS therapies.
6Y8 Occasionally, sleep attacks are reported under dopaminergic treatment in Parkinson disease and RLS patients. 7 Hence, we analyzed data from the Swiss RLS trial (Bassetti et al., submitted), a randomized double-blind 2-sequence, 2-period crossover study that was conducted to determine the hypothesis of noninferiority of pramipexole compared with dual-release, 9 a combination of immediate-and slow-release, L-dopa/benserazide (L/B) in the short-term treatment of RLS, to assess frequency and characteristics of RLS patients with EDS and to evaluate the course of EDS under adequate treatment with pramipexole (PPX) or L/B.
MATERIALS AND METHODS

Ethical Aspects
The protocol, patient information, and informed consent has been reviewed and approved by the institutional review board and has been notified to the Swiss Health Authority.
Study Design
We analyzed data from the Swiss RLS study. This study was conducted to compare noninferiority of pramipexole versus L-dopa in the treatment efficacy of RLS symptoms and periodic leg movements in sleep (PLMS) as multicenter, randomized, double-blind, comparative crossover trial with 2 treatment periods of each 4 weeks. After treatment Period 1 with either PPX or L/B, patients were switched to the respective other treatment (period 2). Crossover washout period between treatments lasted 2 weeks.
Medication
Pramipexole 0.25 to 0.75 mg (Mirapex/Sifro1) and dualrelease L/B 125 to 375 mg (Madopar DR) were administered orally, once daily before bedtime. Drug exposure for each period was 26 to 30 days; the washout period in between treatment periods lasted 2 weeks. There was no evidence of any carryover effect.
Patient Population
Patients aged 25 to 85 years, fulfilling all clinical criteria for diagnosis of idiopathic RLS, presenting RLS symptoms almost every day, and with more than 5 periodic leg movement per hour during bedtime were included. Patients previously treated with PPX, L/B, or another DA, significant diseases other than restless legs syndrome, in particular other sleep-wake disorders, were excluded. 
Outcome Measures
Primary end point of the present study was the change in ESS score under treatment. Secondary outcome measures were efficacy in changes of IRLS-score, PLMS index, sleep quality, and Hospital Anxiety and Depression Scale (HADS). The PLMS index was determined using the PAM-RL Monitor System (IM Systems, Baltimore, Md). 10 
Statistics
We analyzed data from 37 patients (21 women) with a complete data set. Excessive daytime sleepiness was defined as an ESS score of higher than 10. Statistical analysis was performed using SPSS software package version 14 (SPSS Inc., Chicago, Ill). Significant changes of ESS and IRLS under different treatments were estimated by 2-and 3-way repeatedmeasures analysis of variance (general linear model) with the between-subject factors treatment (pramipexole vs L-dopa), group (sleepy vs nonsleepy patients) and the within factor time (baseline-end) followed by post hoc t tests. The W 2 and Student t tests were used to analyze categorical and continuous variables. Pearson product correlations were performed to identify correlations between the individual items. Significance was determined as P e 0.05. All results are expressed as mean (TSD).
RESULTS
Daytime Sleepiness
Period 1
We found an ESS higher than 10 (mean, 13.3 T 2.1) in 12 (32%) and severe EDS, as determined by an ESS greater than 14 in 5 patients (14% of all 37) (Fig. 1) . Epworth Sleepiness Scale was reduced with treatment in sleepy and nonsleepy patients (main effect for Btime[ (F 1,33 = 6.63, P = 0.02) independent from substance (period Â treatment interaction, F 1,33 = 0.5; P = 0.82). However, triple interaction revealed that the effect of treatment differed among the 2 groups (time Â group Â treatment interaction, F 1,33 = 4.3, P = 0.05). In sleepy patients, PPX significantly improved ESS from 14.3 T 2.3 to 10.5 T 5.2 (n = 6, P = 0.05), whereas under L-dopa treatment, ESS only slightly improved from 12.3 T 1.5 to 11 T 2.8 (n = 6, not significant). In the nonsleepy patients, ESS did not significantly change (PPX, from 7.4 T 2.2 to 8.1 T 2.9; and L/B, from 6.0 T 2.8 to 4.7 T 1.6).
Under PPX (L/B) therapy in 3 (2) of all 37 patients, ESS score deteriorated to a score greater than 10. Nevertheless, RLS symptoms (IRLS and PLMS) improved in these patients. No sleep attack occurred.
Period 2
We found 11 patients (30%) with ESS greater than 10 (mean, 12.5 T 1.4) and 1 patient with ESS greater than 14. In (all) sleepy patients, ESS improved under therapy (12.6 T 1.4 to 11.2 T 2.9, P = 0.07). Taking into account the different medications used, again, there was no significant change of ESS under L-dopa treatment (12.6 T 1.6 to 12 T 3 [n = 8, not significant]), whereas in PPX, there was an improvement of ESS from 12.3 T 1.2 to 9 T 2. Because of a very small number (n = 3) of sleepy patients treated with PPX, no statistical analysis was performed.
Differences and Correlations
Sleepy RLS patients were younger than nonsleepy RLS patients (50.4 T 7.5 vs 59.6 T 11.6, P = 0.007). No other statistical differences or correlations in sex, body mass index (BMI), medication, idiopathic IRLS score, depression, anxiety, or PLMS index were found between sleepy and nonsleepy RLS patients. For further details, please see Table 1 . None of the evaluated factors was able to predict the development of new sleepiness (on ESS).
Restless Legs Symptoms
Period 1
IRLS improved within period 1 (main effect of time, F 1,33 = 21.3, P = 0.001) with either medication (no time Â treatment interaction, F 1,33 = 0.1, P = 0.9). Post hoc t test confirmed that mean IRLS score of the 37 patients at baseline was 22.8 T 6.9 and improved to a mean of 15.4 T 8.2 (P G 0.001) under treatment with L-dopa (n = 17) or PPX (n = 20).
The effect of PPX and L-dopa on idiopathic RLS was quiet similar in sleepy and nonsleepy patients (time Â group Â treatment interaction, F 1,33 = 1.45, P = 0.24) ( Table 1 ). 
